Smith and Nephew has introduced a handheld imaging device, MolecuLight i:X, in Europe to allow immediate measurement of wound surface area.
Manufactured by Canadian medical imaging firm MolecuLight, the device uses fluorescence to visualise the presence and distribution of potentially harmful bacteria in wounds.
MolecuLight i:X is developed to address the concerns with current, inaccurate wound assessments made with the naked eye.
The device is intended to facilitate the right treatment at the right time for the patient. It also aids in guide sampling and debridement of wounds, monitors its progression, improves patient engagement, and simplifies documentation.
Smith and Nephew Wound global marketing senior vice-president Paolo Di Vincenzo said: “The MolecuLight i:X enables healthcare professionals to see what they have never been able to see before.
“It strongly complements our range of advanced wound care products and we believe it is set to start a revolution in wound care clinical practice.”
The MolecuLight i:X Imaging Device obtained Health Canada approval as well as CE-Mark in Europe.
As per the clinical data obtained during wound assessments, integration of the device into standard of care enabled more objective medical decisions and led to about nine times faster wound healing and 54% more accurate swabbing.
MolecuLight founder, chief scientific officer and director Dr Ralph DaCosta said: “For the first time, clinicians can accurately sample a wound in situ to determine if bacteria are present as well as more effectively debride a wound under fluorescence visualisation.
“These are fundamental areas of everyday wound care that have remained suboptimal for too long, until now.”